Please login to the form below

Not currently logged in
Email:
Password:

Bedrock appoints new commercial director

Dr Laura Ciccolini brings experience from the Biopharm Group and Sigma Aldrich

Bedrock Healthcare Communications Dr Laura CiccolinaUK-based medical communications agency Bedrock has appointed Dr Laura Ciccolini to be its new commercial director.

She has over 15 years experience in life sciences and biochemical engineering and previously served as a business development manager for chemical, life science and biotech company Sigma Aldrich.

Her prior roles also include executive director and commercial director at pharma and biotech equipment supplier the Biopharma Group.

In her new senior management position at Bedrock she will be tasked with supporting and driving the agency's growth, working across its insights, med comms and multimedia practices.

Ciccolini will report to CEO David Youds, who said: “I am delighted Laura has joined our team and brings such strong experience.

“Laura will be instrumental in shaping the way we connect with clients and their audiences, as well as providing commercial leadership within the agency to ensure we meet our goals as an organisation.”

21st September 2016

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....
Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...

Infographics